Current Challenges and Future Developments for Drug Safety in Emerging Markets
10/14/2010
Monica Rusu | pharmacoviligance | drug safety | emerging markets | risk management | global PV systems | risk management plans | pharmacovigilance strategies | patient safety | risk management strategies | Abbott
Monica Rusu | pharmacoviligance | drug safety | emerging markets | risk management | global PV systems | risk management plans | pharmacovigilance strategies | patient safety | risk management strategies | Abbott
Drug safety has never been more important. Patient's attitudes to risk have changed significantly and negative perceptions of a product can have devastating effects on the reputation of the developer.
Regulatory hurdles and rule changes on risk management have also increased the pressures on drug developers to ensure sound pharmacovigilance processes are in place.
Presented by Dr. Monica Rusu Director, Pharmacovigilance EELA, Abbott Products GmbH, at IQPC's Pharmacovigilance and Risk Management Strategies in June 2010.
Rusu discusses:
- The local regulatory environment and expectations of competent authorities
- Developing risk management plans to conform to differen regulatory standards
- Challenges for the global PV systems
- Identifying commonalities across the emerging markets for a more standardised approach to risk management
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
-
Case Study: Design Space Development for Large Molecules in Upstream Processing Concept -
Portable Quality By Design -
Das Modell der EFPIA zur Verifikation pharmazeutischer Produkte -
Effective Internal and External Partnerships in Oncology Trials -
UCB Case Study: Open Innovation and Risk Sharing Partnerships – What are the Benefits and Practicalities? -
Reviewing Recent European Cases to Implement Best Practice Patent Filing Strategies for the Future -
Dealing with Changes in the Marketplace: Mergers and Acquisitions in the CRO Industry and their Impact on Sponsors -
Assessing the Global Impact of Standardisation on Manufacturers: Is it Really Worth it? -
Treating Asthma with Monoclonal Antibody Based Drugs: Past Experience and Future Prospects -
Delivering and Sustaining Lean on the Shopfloor
You Should Check Out:
* = required.
Not a member yet? Sign up
Events of Interest
-
Adverse Event Reporting Online Training Course 2011
August 3, 2011
Register Now -
Electronic Laboratory Notebooks Online
December 2, 2011
Register Now -
Site Quality Management and Risk-Based Monitoring: A New Approach
December 4, 2012
Register Now -
Distinguishing Between ELNs and LIMS
November 21, 2011
Register Now




Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!